

No.10-27 June 9, 2010 Eisai Co., Ltd.

EISAI ENTERS INTO U.S. LICENSE AGREEMENT WITH HELSINN HEALTHCARE S.A. FOR NEW COMBINATION ANTIEMETIC AGENT

prevention of covers the distribution of covers the distribution of the covers and the covers are covered as a cover of the covers and the covers are covered as a covered as

₁) receptor antagonist, and palonosetron (generic name, brand name: Aloxi®), a serotonin-3 (5-HT₃) receptor antagonist.

Under the terms of the agreement, Helsinn Healthcare S.A. will be responsible for conducting clinical trials, obtaining regulatory approvals, and holding the New Drug Application in the United States. If approved, the new products will be co-promoted by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. Additionally, Helsinn's manufacturing affiliate in Ireland, Helsinn Birex Pharmaceuticals Ltd., will be responsible for the manufacture and supply of finished products for clinical and commercial use in the United States. Eisai Inc. will book sales of the products in the United States.

Helsinn Healthcare SA is entering Phase III clinical tria

[Notes to editors]

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in Ireland and the United States. Helsinn's business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Group in-licenses early to late stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC), development to the filing for and attainment of their market approval worldwide. Helsinn's products are sold directly through the Group's subsidiaries or out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice. The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn's cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers.

For more information about the Helsinn Group, please visit the website: www.helsinn.com